KDR and hepatocellular carcinoma: Alpinumisoflavone has anti-angiogenic potential as it inhibits vascular endothelial growth factor receptor-2 (VEGFR2) [33], and VEGFR2-targeted co-treatment with ramucirumab and sorafenib is already proven to be effective in improving the overall survival of HCC patients, which implies the potential of alpinumisoflavone as a therapeutic aid [34].